Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA budget

This article was originally published in The Gray Sheet

Executive Summary

The House Appropriations committee passes the $18.4 bil. "Agriculture, Rural Development, FDA, and Related Agencies Appropriations" bill for FY 2007 on May 9. For the second year in a row, the legislation contains an amendment forwarded by Congressman Maurice Hinchey (D-N.Y.) that would prohibit scientists and doctors with conflicts of interest from serving on FDA advisory panels. In October 2005, Congress approved a reconciled version of the FY 2006 spending bill with a watered-down version of Hinchey's conflict-of-interest provision (1"The Gray Sheet" Oct. 31, 2005, In Brief). The FY 2007 bill, which allots $229 mil. for the Center for Devices and Radiological Health, will now be taken up by the full House (2"The Gray Sheet" Feb. 13, 2006, p. 6)...

You may also be interested in...



FDA Budget Request Proposes New User Fee For Facility Reinspections

FDA is proposing a new mandatory user fee that would require device and drug manufacturers to pay for reinspections of manufacturing facilities cited for violations

FDA panel conflicts of interest

Reconciled FY 2006 FDA appropriations bill passes the House Oct. 28 with a "very watered-down" version of an advisory committee conflict-of-interest (CoI) provision, according to Rep. Maurice Hinchey (D-N.Y.), who succeeded in adding a CoI amendment to the original House bill in June. The final language requires that panel member conflicts of interest and waivers for conflicts be posted on FDA's website at least 15 days prior to a meeting or as soon as possible if the conflict is identified closer to the meeting date. Hinchey's amendment would have prohibited FDA from granting CoI waivers (1"The Gray Sheet" June 13, 2005, In Brief)...

Ex-Janssen India Chief To Lead PE-Controlled Bharat Serums

Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.

UsernamePublicRestriction

Register

MT023544

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel